You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)

Recruiting
  • Esophageal Carcinoma
  • Neoadjuvant Immunotherapy
  • PD-1 blockade
  • +2 more
  • Beijing, Beijing, China
    Qin li
Mar 8, 2023

HNSCC, Radiotherapy, PD-1 Trial in Guangzhou (PD-1inhibitor, concurrent chemoradiotherapy)

Recruiting
  • HNSCC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Advanced Breast Cancer, Breast Tumor Malignant Female Trial in Guangzhou (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

Completed
  • Advanced Breast Cancer
  • Breast Neoplasm Malignant Female
  • AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Apr 11, 2023

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

Carotid Artery Plaque, Pd-1 Inhibitors Trial in Hangzhou (PD-1 inhibitor)

Recruiting
  • Carotid Artery Plaque
  • Pd-1 Inhibitors
  • PD-1 inhibitor
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital of Zhejiang University, School of
Sep 17, 2022

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Head Neck Cancer, Intratumoral Injection Trial in Chicago (RiMO-301)

Recruiting
  • Head Neck Cancer
  • Intratumoral Injection
  • Chicago, Illinois
    University of Illinois at Chicago
Apr 28, 2023

Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1 Trial in Changchun (nCRT ? (CapeOX+Sintilimab)×6 ?

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • +2 more
  • nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
  • Changchun, Ji Lin, China
    First Hospital of Jilin University
Aug 11, 2023

Neoadjuvant Chemo, PD-1 Antibody, Radiotherapy Trial (neoadjuvant chemo combined with PD-1 antibody + radical radiotherapy)

Not yet recruiting
  • Neoadjuvant Chemotherapy
  • +3 more
  • neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
  • (no location specified)
Sep 21, 2022

Esophageal Tumor Metastatic, Esophageal Cancer Stage IVb Trial in Beijing (drug, biological, radiation)

Recruiting
  • Esophageal Neoplasm Metastatic
  • Esophageal Cancer Stage IVb
  • TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
  • +3 more
  • Beijing, Beijing, China
    Cancer hospital, CAMS
Oct 19, 2023

Rectal Cancer Trial (PD-1, SCRT, Bevacizumab)

Not yet recruiting
  • Rectal Cancer
  • PD-1
  • +5 more
  • (no location specified)
Dec 6, 2022

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Chemoimmunotherapy
  • neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
  • (no location specified)
Feb 14, 2023

Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

Not yet recruiting
  • Solid Tumor, Adult
  • +2 more
  • (no location specified)
Dec 14, 2022

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and

Not yet recruiting
  • Colorectal Neoplasms
  • Beijing, Xicheng Dis, China
    Beijing Friendship Hospital, Capital medical University
Sep 5, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Squamous Cell Carcinoma of the Head and Neck Trial in Stanford ([18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.)

Completed
  • Squamous Cell Carcinoma of the Head and Neck
  • [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
  • Stanford, California
    Stanford Hospital and Clinics
Dec 1, 2022

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:

Not yet recruiting
  • Hepatocellular Carcinoma Non-resectable
  • transarterial therapies
  • (no location specified)
Nov 27, 2022

Advanced Solid Tumor Trial in Xuzhou (Oncolytic Virus Injection(Revottack)+PD-1)

Not yet recruiting
  • Advanced Solid Tumor
  • Oncolytic Virus Injection（Revottack）+PD-1
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Dec 1, 2022

Hepatocellular Carcinoma Trial in Yichang (Sintilimab)

Recruiting
  • Hepatocellular Carcinoma
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Sep 1, 2023

Head and Neck Squamous Cell Carcinoma Trial (Pembrolizumab, Cisplatin, Paclitaxel-albumin)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 25, 2023

Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

Recruiting
  • Gastric Cancer
  • HER2-low-expressing Gastric Cancer
  • Shanghai, China
    Shanghai East Hospital
Oct 9, 2023

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023